IOBT_OUT_1 [2025-03-25 10:54:38 -0400] 2134 Bytes | 589 tokens | Cum: 589 tkns (7.36% of 8k)
==========================================================================

Alright, let’s light it up, because it's 10:54:36 AM on Tue Mar 25, 2025 -0400, and I'm charging into IO Biotech (IOBT), popping from 1 to 1.28. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for IO Biotech:

C1 - Mar-18-25 08:00AM - IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025
C2 - Mar-04-25 04:17PM - IO Biotech Reports 2024 Business Highlights
C3 - Feb-23-25 12:07PM - IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
C4 - Feb-20-25 08:05AM - IO Biotech to Present at the 45th Annual Cowen Health Care Conference
C5 - Feb-04-25 08:05AM - IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
C6 - Jan-10-25 11:10AM - IO Biotech enrols all subjects in Phase II trial of cancer combination therapy
C7 - Jan-09-25 08:05AM - IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
C8 - Dec-20-24 08:05AM - IO Biotech secures up to 57.5 million in debt financing from the European Investment Bank

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on IO Biotech (IOBT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

IOBT_OUT_3 [2025-03-25 10:54:40 -0400] 1048 Bytes | 288 tokens | Cum: 879 tkns (10.99% of 8k)
==========================================================================

Showing C1 (chunk 1 of 7): C1:
**IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025**
Date: Mar-18-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/18/3044458/0/en/IO-Biotech-Named-Among-Fast-Company-s-World-s-Most-Innovative-Companies-of-2025.html

March 18, 2025 08:00 ET| Source:IO BiotechIO Biotech

– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines –

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. Fast Company recognizes 609 organizations across 58 sectors and regions. IO Biotech has been recognized for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IOBT_OUT_5 [2025-03-25 10:54:42 -0400] 981 Bytes | 287 tokens | Cum: 1168 tkns (14.60% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T10:06:05Z - Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Akebia Therap...
A2 - 2025-03-18T13:50:11Z - IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 By Investing.com...
A3 - 2025-03-18T12:17:49Z - IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 | Taiwan News | Mar....
A4 - 2025-03-18T12:11:36Z - IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025...
A5 - 2025-03-18T02:16:09Z - Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Increases By 32.9%...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IOBT_OUT_7 [2025-03-25 10:54:43 -0400] 1038 Bytes | 287 tokens | Cum: 1457 tkns (18.21% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Akebia Therapeutics (NASDAQ:AKBA), AGM Gr Hldgs (NASDAQ:AGMH)**Date: 2025-03-20Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/03/44412265/why-five-below-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarketShares of Five Below, Inc. FIVE rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.

Five Below reported adjusted earnings of $3.48 per share, beating market estimates of $3.38 per share. The company's sales came in at $1.391 billion versus expectations of $1.386 billion.

Five Below shares jumped 11.9% to $84.59 in the pre-market trading session.

Here are some other stocks moving in pre-market trading.

Gaine

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IOBT_OUT_9 [2025-03-25 10:54:45 -0400] 1038 Bytes | 291 tokens | Cum: 1750 tkns (21.88% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): rs

SAG Holdings Limited SAG gained 77.8% to $1.20 in pre-market trading after jumping 7% on Wednesday. OptiNose, Inc. OPTN rose 59.3% to $9.56 in pre-market trading. Paratek Pharmaceuticals announced plans to acquire Optinose in a deal worth up to $330 million. ProAssurance Corporation PRA gained 50.6% to $23.41 in pre-market trading after the company announced it will be acquired by The Doctors Company for $25.00 per share in cash. AGM Group Holdings Inc. AGMH gained 40.3% to $0.1010 in pre-market. AGM Group Holdings announced the receipt of Nasdaq notification regarding minimum bid requirements. DevvStream Corp. DEVS gained 28.7% to $0.4761 in pre-market trading after jumping 8% on Wednesday. Emerson Radio Corp. MSN gained 27.2% to $0.56 in pre-market trading. CIMG Inc. IMG gained 21.1% to $0.5812 in pre-market trading after the company announced its subsidiary signed a business coope

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IOBT_OUT_11 [2025-03-25 10:54:46 -0400] 1205 Bytes | 339 tokens | Cum: 2091 tkns (26.14% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-23T17:07:00Z - IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
B2 - 2024-11-07T15:00:00Z - IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
B3 - 2024-09-14T06:30:00Z - IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
B4 - 2024-05-23T12:30:00Z - IO Biotech to Present at Jefferies Global Healthcare Conference
B5 - 2024-05-14T11:55:00Z - IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
B6 - 2024-04-24T20:30:00Z - IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IOBT_OUT_13 [2025-03-25 10:54:51 -0400] 800 Bytes | 197 tokens | Cum: 2290 tkns (28.62% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/23/3030818/0/en/IO-Biotech-Announces-New-Preclinical-Data-for-Additional-Pipeline-Candidate-Presented-at-the-AACR-IO-Conference.htmlIO Biotech presented new preclinical data on its TGF-β-directed peptide vaccine, IO170, which showed reduced tumor growth in cancer models without causing systemic toxicity. The findings support the continued development of this immune-modulatory vaccine as a novel approach for treating a wide range of cancers.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IOBT_OUT_15 [2025-03-25 10:54:53 -0400] 1098 Bytes | 307 tokens | Cum: 2663 tkns (33.29% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-04 8-K Item2.02 Results of Oper and Fin Cond.

As discussed below, IO Biotech, Inc., a Delaware corporation (the Company), issued a press release on March 4, 2025. In its press release, the Company disclosed a cash and cash equiv balance of approximately $60 mill...

S2 - 2024-12-20 8-K Item1.01. Entry into a Material Definitive Agrmt.

Finance Contract and Guarantee Agrmt

On December 19, 2024, IO Biotech ApS, a private limited liability company incorporated in Denmark and wholly-owned subsidiary (the Borrower) of IO Biotech, Inc., a Delaware corporat...

S3 - 2024-11-12 10-Q PART IFINANCI AL INFO

Item 1. Interim Financi al Stmnts (Unaudited)

IO BIOTECH, INC.

Cons Balance Sheets

(In thousands, except share and per share amounts)

(unaudited)

September 30, 2024

December 31, 2023

Assets

Curr assets

Cash and cash...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IOBT_OUT_17 [2025-03-25 10:54:59 -0400] 928 Bytes | 222 tokens | Cum: 2887 tkns (36.09% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item2.02 Results of Operations and Financial Condition.

As discussed below, IO Biotech, Inc., a Delaware corporation (the Company), issued a press release on March 4, 2025. In its press release, the Company disclosed a cash and cash equivalents balance of approximately $60 million as of December 31, 2024.

Because the Companys consolidated financial statements for the year ended December 31, 2024 have not yet been finalized or audited, the preliminary statement of the Companys cash and cash equivalents as of December 31, 2024 in this Item 2.02 is subject to change, and the Companys actual cash and cash equivalents as of December 31, 2024 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate....

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IOBT_OUT_19 [2025-03-25 10:55:20 -0400] 4221 Bytes | 1178 tokens | Cum: 4164 tkns (52.05% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+----------------------+------------------------+----------------------+-----------------------+
| Volume: 702,643 | SMA50: 36.67% | Market Cap: 84.21M | Option/Short: No / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+---------------------+----------------------+----------------------+------------------------+----------------------+-----------------------+
| Avg Volume: 135.03K | SMA200: 18.26% | Shs Outstand: 65.88M | Short Float: 0.07% | Employees: 68 | EPS Surprise: -25.22% |
+---------------------+----------------------+----------------------+------------------------+----------------------+-----------------------+
| Rel Volume: 23.86 | Perf Week: 41.94% | Shs Float: 48.45M | Short Ratio: 0.24 | Debt/Eq: 0.03 | P/E: - |
+---------------------+----------------------+----------------------+------------------------+----------------------+-----------------------+
| RSI (14): 76.48 | Perf Month: 21.74% | Inst Own: 22.50% | Short Interest: 0.03M | Sales Y/Y TTM: - | Earnings: Nov 12 BMO |
+---------------------+----------------------+----------------------+------------------------+----------------------+-----------------------+
| ATR (14): 0.10 | Perf Quarter: 68.18% | Insider Own: 26.46% | Beta: 0.18 | ROE: -78.50% | |
+---------------------+----------------------+----------------------+------------------------+----------------------+-----------------------+
| SMA20: 36.23% | Index: - | Insider Trans: 0.38% | Sales Q/Q: - | ROI: -122.26% | |
+---------------------+----------------------+----------------------+------------------------+----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: IO Biotech, Inc. Common Stock
Market Cap: N/A
Shares Outstanding: N/A
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -90340000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.275
Average Volume: 150600.23
30-Day High: 1.275
30-Day Low: 0.8593

[Detailed Financials: Q3 2024]
- Total Assets: $89,945,000.0
- Total Liabilities: $17,380,000.0
- Total Equity: $72,565,000.0
- Current Assets: $86,244,000.0
- Current Liabilities: $16,055,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.36

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $111,467,000.0
- Total Liabilities: $15,195,000.0
- Total Equity: $96,272,000.0
- Current Assets: $107,652,000.0
- Current Liabilities: $13,723,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.31

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

IOBT_OUT_21 [2025-03-25 10:55:27 -0400] 676 Bytes | 167 tokens | Cum: 4605 tkns (57.56% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

IOBT_IN_23 [2025-03-25 10:55:27 -0400] 126 Bytes | 29 tokens | Cum: 4726 tkns (59.08% of 8k)
==========================================================================

====================================
[2025-03-25 07:55:27] # Analysis Completed
Elapsed Time: 51.63 seconds